Abstract
In these experiments we have tested the effect of bis(acetato)tetrakis (imidazole) copper(II) on the release and uptake of 14C-GABA and 3H-glutamate from brain slices and brain cortical synaptosomes. Cu(OAc)2(Im)4 in concentrations ranging from 1 to 100 μM has increased the release of GABA and glutamate from brain slices and synaptosomal preparations in a dose-related manner when the effect on GABA release is two-fold greater than glutamate and 10-fold greater than alanine. Pretreatment with a GABA uptake inhibitor such as 1–2 mM nipecotic acid has no effect on 14C-GABA release, whereas hydroxy aspartate, the glutamate uptake inhibitor, has elevated the stimulated release of glutamate. Copper(II) chloride, the inorganic form of copper, had no significant effect either on GABA release or on glutamate release. The stimulated release of exogenous GABA and glutamate was Ca2+-dependent, because it was inhibited by EGTA, and neuronal, because it was blocked by tetrodotoxin. The recent results can explain the anticonvulsant activity of Cu(OAc)2(Im)4 against strychnine-induced seizures by increasing the net release of GABA from cortical neurons.
Similar content being viewed by others
References
J. R. J. Sorenson, Copper chelates as possible active forms of antiarthritic agents, J. Med. Chem. 19, 135–148 (1976).
J. R. J. Sorenson, L. W. Oberley, and V. Kishore, Copper complexes: a physiological approach to the treatment of inflammatory diseases, Inorg. Chim Acta 91, 285–294 (1984).
J. R. J. Sorenson, K. Ramakrishna, and T. M. Rolniak, Antiulcer activities of d-penicil lamine copper complexes, Agents Actions 12(3), 408–411 (1982).
J. R. J. Sorenson, Copper complexes offer a physiological approach to treatment of chronic diseases, Proc. Med. Chem. 26, 437–568 (1989).
S. E. Gandy, M. G. Buse, J. R. J. Sorenson, et al., Attenuation of streptozotocin diabetes with superoxide dismutase like copper(II) (3,5-diisopropyl-salicylate)2 in the rat, Diabetologia 24(6), 437–440 (1993).
A.-S. Abdul-Ghani, A. L. AbuHijleh, N. Nahas, et al., Hypoglycemic effect of copper(II) acetate imidazole complexes, Biol. Trace Element Res. 54, 143–151 (1996).
J. R. J. Sorenson, Copper chelates as possible active metabolites of the antiarthritic and antiepileptic drugs, J. Appl. Nutr. 32, 4–9 (1980).
B. L. Booth, E. Pitters, B. Mayer, et al., Down regulation of porcine heart diaphorase reactivity by trimanganese hexakis (3,5-diisopropyl salicylate) Mn3(3,5-DIPS)6, and down regulation of nitric oxide synthase reactivity by Mn3(3,5-DIPS)6 and Cu(II)2(3,5-DIPS)4, Metal-Based Drugs 6, 111–120 (1999).
G. Morgant, N.-H., Dung, J.-C. Daran, et al., Low-temperature crystal structures of tetrakis-μ-3,5-diisopropylsalicylatobis-dimethyl formamido dicopper (II) and tetrakis-μ-3,5-diisopropylsalicylatobis-diethyletheratodicopper(II) and their role in modulating polymorphonuclear leukocyte activity in overcoming seizures, J. Inorg. Biochem. 81, 11–22 (2000).
J. R. J. Sorenson, L. S. F. Soderberg, L. W. Chang, et al., Copper-, iron-, manganese- and zinc-3,5-diisopropylsalicylate complexes increase survival of gamma-irradiated mice, Eur. J. Med. Chem. 38, 221–229 (1993).
B. Viossat, J.-C. Duran, G. Savouret, et al., Low temperature (180 K) crystal structure, electron paramagnetic sesonance spectroscopy, and propitious anticonyulsant activities of Cu(II)2(aspirinate)4(DMF)2 and other Cu(II)2(aspirinate)4 chelates, J. Inorg. Biochem. 96, 375–385 (2003).
A.-S. Abdul-Ghani, A. Abu-Hijleh, and M. Qazzaz, The effect of bis(acetato)tetrakis(imidazole)copper(II) in delaying the onset and reducing the mortality rate of strychnine and thiosemicarbazide induced convulsions. Biol. Trace Element Res., 101, 87–95 (2004).
P. Y. Boukan, E. A. Busnot, F. Busnot, et al., Structure du di-μ-acetato-bis[acetato bis(methyl-1 imidazol) cuivre(II)]hexahydrate, Acta Crystallogr. B38, 2458–2461 (1982).
P. Lemoine, B. Viossat, G. Morgant, et al., Synthesis, crystal structure, EPR properties and anticonvulsant activities of binuclear and mononuclear 1,10-phenanthroline and salicylate ternary copper(II) complexes, J. Inorg. Biochem. 89, 18–28 (2002).
A. L. AbuHijleh, C. Wood, and I. Y. Ahmed, Synthesis and molecular structure of monomeric copper(II) acetate with 2-methylimidazole and 1,2-dimethylimidazole, Inorg. Chim. Acta 190, 11–17 (1991).
A. L. AbuHijleh and C. Woods, Synthesis, spectroscopic and structural characterization of bis(acetato)tetrakis(imidazole) copper(II): a model complex of DNA binding, Inorg. Chim. Acta 194, 9–14 (1992).
E. G. Gray and W. P. Whittaker, The isolation of nerve ending from brain; an electron-microscopic study of cell fragments derived by homogenization and centrifugation, J. Anat. 96, 79–88 (1962).
H. F. Bradford, G. W. Bennett, and A. J. Thomas, Depolarizing stimuli and the release of physiologically active amino acids from suspensions of mammalian synaptosomes, J. Neurochem. 21, 495–505 (1973).
J. R. J. Sorenson, D. O. Rauls, K. Ramakrishna, et al., in Trace Substances in Environmental Health—XIII. Anticonvulsant Activity of Some Copper Complexes, D. D. Hemphill (ed.), University of Missouri Press, Columbia, MO, pp. 360–367 (1979).
H. H. A. Dollwet, J. B. McNicholas, A. Pezesk, et al., Superoxide dismutase-mimetic activity of antiepileptic drug copper complexes, Trace Elements Med. 4, 13–20 (1987).
G. Morgant, N.-H. Dung, J.-C. Daran, et al., Low-temperature crystal structures of tetrakis-μ-3,5-diisopropylsalicylatobis-dimethyl formamido dicopper (II) and tetrakis-μ-3,5-diisopropylsalicylatobis-diethyletheratodicopper(II) and their role in modulating polymorphonuclear leukocyte activity in overcoming seizures, J. Inorg. Biochem. 81, 11–22 (2000).
H. F. Bradford, in Biochemistry and Neurology, H. F. Bradford and C. D. Marsden, eds., Academic, London, pp. 195–212 (1976).
S. Simler, L. Ciesiclski, M. Maitre, et al., Effect of sodium n-dipropyl acetate on audiogenic seizures and brain γ-amino butyric acid levels, Biochem. Pharmacol. 22, 1701 (1973).
R. M. Pinder, R. N. Brogden, T. M. Speight, et al., Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness, Drugs 13(6), 401–421 (1977).
B. S. Meldrum, Epilepsy and gamma-amino butyric acid-mediated inhibition, Int. Rev. Neurobiol. 17, 1–36 (1975).
A.-S. Abdul-Ghani, J. Coutinho-Neto, D. Druce, et al., Effects of anti-convulsants on the in vivo and in vitro release of GABA, Biochem. Pharmacol. 30, 363–368 (1981).
A.-S. Abdul-Ghani, P. J. Norris, C. C. T. Smith, et al., Effect of μ-acetylenic GABA and γ-vinyl GABA on synaptosomal release and uptake of GABA, Biochem. Pharmacol. 30(11), 1203–1209 (1981).
O. D. Dolly, C. K. Tse, J. W. Spokes, and C. R. Diniz. Effect of β-bangarotoxin and Tityus-toxin on uptake and release of neurotransmitters, Biochem. Soc. Trans. 6, 652–654 (1978).
J. Coutinho-Neto, A.-S. Abdul-Ghani, P. J. Norris, et al., The effect of Scorpiom venom toxin on the release of amino acid neurotransmitters from cerebral cortex in vivo and in vitro, J. Neurochem. 35(3), 558–565 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abdul-Ghani, AS., Abu-Hijleh, AL., Qazzaz, M. et al. Stimulated release of exogenous GABA and glutamate from cerebral cortical synaptosomes and brain slices by bis (acetato) tetrakis (imidazole) copper(II) complex. Biol Trace Elem Res 108, 205–214 (2005). https://doi.org/10.1385/BTER:108:1-3:205
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/BTER:108:1-3:205